Form 4: Merit Medical Systems CFO Raul Parra Jr. Reports Stock Transactions
SEC Form 4
Raul Parra Jr., CFO and Treasurer of Merit Medical Systems, reports acquisition and disposal of company stock, including shares from performance stock units, tax surrender, restricted stock units, and open market sales.
Summary
- Raul Parra Jr., CFO and Treasurer of Merit Medical Systems, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On February 27, 2025, Parra acquired 20,760 shares related to performance stock units at $0 cost and surrendered 8,309 shares for payroll taxes at a price of $98.5.
- On February 28, 2025, Parra acquired 7,840 restricted stock units (RSUs) at $0 cost and sold 12,451 shares in the open market at a weighted average price of $98.81.
- Parra also holds non-qualified stock options with various exercise prices and expiration dates.
- Following these transactions, Parra directly owns 24,201 shares and indirectly owns 2,770 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing primarily reflects routine stock transactions. The open market sale is slightly negative, but the acquisition of shares through performance units and RSUs is slightly positive.
Positives
- The acquisition of shares through performance stock units suggests the achievement of certain company performance goals.
- The grant of restricted stock units aligns the executive's interests with the long-term performance of the company.
Negatives
- The sale of 12,451 shares on the open market could be interpreted negatively, although it may be for personal financial reasons.
- Surrendering 8,309 shares for payroll taxes reduces the executive's holdings.
Risks
- Executive stock sales can sometimes signal a lack of confidence in the company's future performance, although this is not necessarily the case.
- Changes in executive compensation structures, such as the vesting of RSUs, could impact executive motivation and retention.
Industry Context
Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's view of the company's prospects. Form 4 filings are a standard part of regulatory compliance.
Comparison to Industry Standards
- Executive compensation packages in the medical device industry often include a mix of salary, stock options, and restricted stock units to align executive incentives with shareholder value.
- The vesting schedules for RSUs (three equal annual installments) are typical in the industry.
- Stock option grants with varying exercise prices and expiration dates are also a common practice to incentivize long-term performance.
Stakeholder Impact
- Shareholders may scrutinize the stock sales for insights into the executive's confidence in the company.
- Employees holding company stock or options may be interested in the executive's transactions.
Key Dates
| Date | Description |
|---|---|
| 02/26/2021 | Date from which non-qualified stock options become exercisable in equal annual installments (5,361 shares at $37.71). |
| 03/19/2022 | Date from which non-qualified stock options become exercisable in equal annual installments (9,681 shares at $56.25). |
| 02/28/2022 | Date of grant for performance stock units that resulted in the acquisition of 20,760 shares. |
| 02/28/2023 | Date from which non-qualified stock options become exercisable in equal annual installments (14,570 shares at $65.03). |
| 02/28/2024 | Date from which non-qualified stock options become exercisable in equal annual installments (13,576 shares at $70.58). |
| 02/27/2025 | Date of acquisition of 20,760 shares from performance stock units and surrender of 8,309 shares for payroll taxes. |
| 02/28/2025 | Date of grant of 7,840 restricted stock units and sale of 12,451 shares in the open market. |
| 03/03/2025 | Date of Form 4 filing. |
| 02/26/2027 | Expiration date for non-qualified stock options (5,361 shares at $37.71). |
| 03/19/2028 | Expiration date for non-qualified stock options (9,681 shares at $56.25). |
| 02/28/2029 | Expiration date for non-qualified stock options (14,570 shares at $65.03). |
| 02/28/2030 | Expiration date for non-qualified stock options (13,576 shares at $70.58). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.